CD99 Expression and Prognostic Impact in Glioblastoma: A Single-Center Cohort Study.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409 (Electronic) Linking ISSN: 20734409 NLM ISO Abbreviation: Cells Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI

Glioblastoma*/drug therapy; Adult ; Humans ; Cohort Studies ; Prognosis ; Retrospective Studies ; Temozolomide/therapeutic use ; 12E7 Antigen

Glioblastoma is the most frequent and aggressive brain tumor in adults. This study aims to evaluate the expression and prognostic impact of CD99, a membrane glycoprotein involved in cellular migration and invasion. In a cohort of patients with glioblastoma treated with surgery, radiotherapy and temozolomide, we retrospectively analyzed tumor expression of CD99 by immunohistochemistry (IHC) and by quantitative real-time polymerase chain reaction (qRT-PCR) for both the wild type (CD99wt) and the truncated (CD99sh) isoforms. The impact on overall survival (OS) was assessed with the Kaplan-Meier method and log-rank test and by multivariable Cox regression. Forty-six patients with glioblastoma entered this study. Immunohistochemical expression of CD99 was present in 83%. Only the CD99wt isoform was detected by qRT-PCR and was significantly correlated with CD99 expression evaluated by IHC (rho = 0.309, p = 0.037). CD99 expression was not associated with OS, regardless of the assessment methodology used ( p = 0.61 for qRT-PCR and p = 0.73 for IHC). In an exploratory analysis of The Cancer Genome Atlas, casuistry of glioblastomas CD99 expression was not associated with OS nor with progression-free survival. This study confirms a high expression of CD99 in glioblastoma but does not show any significant impact on survival. Further preclinical studies are needed to define its role as a therapeutic target in glioblastoma.

Cancer Cell. 2010 Jan 19;17(1):98-110. (PMID: 20129251)
Oncotarget. 2016 Nov 29;7(48):79925-79942. (PMID: 27835596)
JCO Oncol Pract. 2023 Apr;19(4):180-189. (PMID: 36638331)
Oncogene. 2007 Oct 11;26(46):6604-18. (PMID: 17471235)
JAMA. 2015 Dec 15;314(23):2535-43. (PMID: 26670971)
Biomedicines. 2023 Jan 22;11(2):. (PMID: 36830847)
Genes Cancer. 2012 Sep;3(9-10):535-49. (PMID: 23486730)
Anticancer Res. 2013 Jun;33(6):2525-33. (PMID: 23749904)
Front Oncol. 2021 Nov 03;11:772052. (PMID: 34804975)
PLoS One. 2019 May 23;14(5):e0217393. (PMID: 31120992)
Neurosurg Clin N Am. 2021 Apr;32(2):211-223. (PMID: 33781503)
Science. 2015 Jan 23;347(6220):1260419. (PMID: 25613900)
Leukemia. 2022 Jun;36(6):1685-1688. (PMID: 35422094)
Genes (Basel). 2018 Mar 13;9(3):. (PMID: 29534016)
J Cell Commun Signal. 2018 Mar;12(1):55-68. (PMID: 29305692)
Cancer Cell. 2021 Apr 12;39(4):509-528.e20. (PMID: 33577785)
Oncotarget. 2016 Aug 2;7(31):50535-50547. (PMID: 27409668)
Int J Mol Sci. 2019 Mar 06;20(5):. (PMID: 30845661)
J Mol Biol. 2022 Mar 15;434(5):167402. (PMID: 34958778)
J Neurooncol. 2007 Oct;85(1):11-24. (PMID: 17634744)
PLoS One. 2013 May 30;8(5):e64140. (PMID: 23737970)
Transl Oncol. 2023 Nov;37:101759. (PMID: 37579711)
J Hematol Oncol. 2021 Oct 9;14(1):162. (PMID: 34627328)
Cancer Discov. 2012 May;2(5):401-4. (PMID: 22588877)
Cell. 2013 Oct 10;155(2):462-77. (PMID: 24120142)
BMC Res Notes. 2020 Oct 22;13(1):496. (PMID: 33092634)
Cancers (Basel). 2022 Jun 28;14(13):. (PMID: 35804940)
Sci Transl Med. 2017 Jan 25;9(374):. (PMID: 28123069)
Cell. 2018 Apr 5;173(2):400-416.e11. (PMID: 29625055)
Clin Neuropathol. 2008 May-Jun;27(3):118-28. (PMID: 18552083)
Cancer Immunol Immunother. 2021 Jun;70(6):1557-1567. (PMID: 33215253)
Cell Death Dis. 2012 Nov 15;3:e425. (PMID: 23152061)
Pathology. 2008 Jan;40(1):25-30. (PMID: 18038311)
Neuro Oncol. 2022 Oct 5;24(Suppl 5):v1-v95. (PMID: 36196752)
Cancer Res. 2000 Sep 15;60(18):5134-42. (PMID: 11016640)
Lancet. 2019 Feb 16;393(10172):678-688. (PMID: 30782343)
Nature. 2008 Oct 23;455(7216):1061-8. (PMID: 18772890)
J Transl Med. 2023 Feb 2;21(1):69. (PMID: 36732815)
Nanomedicine. 2020 Oct;29:102236. (PMID: 32535112)
Sci Signal. 2013 Apr 02;6(269):pl1. (PMID: 23550210)
Cancer Cell. 2006 Mar;9(3):157-73. (PMID: 16530701)
J Transl Med. 2023 Jan 16;21(1):28. (PMID: 36647156)
J Neurooncol. 2014 Aug;119(1):59-70. (PMID: 24797829)

MEDnoTE Srl (a spin-off of the University of Trieste)

Keywords: CD99; glioblastoma; immunohistochemistry; prognostic factor; quantitative real-time polymerase chain reaction

YF1K15M17Y (Temozolomide)
0 (CD99 protein, human)
0 (12E7 Antigen)

Date Created: 20240412 Date Completed: 20240415 Latest Revision: 20250117

20250117

PMC11012029

10.3390/cells13070597

38607036